Introduction
A reduction in kidney function encompasses a number of alterations in thyroid hormone metabolism that renders a particular "Nonthyroidal illness" syndrome 1 in patients with chronic kidney disease (CKD), where low levels of both Total (T3) and free triiodothyroinine (fT3) are hallmark fi ndings.
Recent reports suggest that as many as 70% of patients with end-stage renal disease (ESRD) present with low T3 levels, [2] [3] [4] [5] and as many as 20-25% have subclinical hypothyroidism. 6, 7 The underlying pathophysiology of these derangements is likely multifactorial, involving iodine retention, altered serum protein binding capacity, systemic infl ammation and peripheral deiodinase activity. 8, 9 These abnormalities have traditionally been considered as a physiological mechanism to save energy in response to uremic wasting. 10 However, growing evidence suggests T3 to participate in the pathophysiology of endothelial dysfunction, 11 atherosclerosis 12 and cardiac abnormalities 13 of CKD patients. Some studies, with somewhat confl icting results, have also implicated thyroid alterations in the mortality risk of CKD patients. [14] [15] [16] Zoccali et al. 14 were the fi rst to report a positive association between low fT3 levels and all-cause mortality in stable hemodialysis (HD) patients, with similar fi ndings in peritoneal dialysis (PD) patients. 17 We could further confi rm and expand these observations in a cohort of euthyroid incident HD patients, in which the variance of all-cause and cardiovascular (CV) mortality was better explained by T3 than by fT3 levels. 16 In contrast, a study in 87 HD patients could not confi rm these fi ndings, 15 and a more recent retrospective report found that the association between fT3 and all-cause mortality was confounded by the nutritional status of the patients. 5 Whereas existing evidence on the association between thyroid hormones and mortality is limited to studies considering single measurements of hormone levels, it is presently unknown whether thyroid hormone fl uctuation over time impacts on mortality hazards. In apparently healthy individuals, thyroid hormone concentrations show a narrow intra-individual variation, 18 although certain circadian and seasonal (mainly due to seasonal differences in iodine intake) fl uctuations have been observed. 19 In diseased individuals, however, thyroid hormone concentrations seem subjected to a higher fl uctuation as infl uenced among others by wasting syndromes, persistent infl ammation and cardiac comorbidities. 19 No studies, to the best of our knowledge, have assessed variation of thyroid hormones in CKD patients and their association with mortality outcome. Against this background, the objective of the present study was to evaluate the association between both basal levels and longitudinal (3-month) variation of T3, T4 and thyroid stimulating hormone (TSH), and all-cause and cause-specifi c mortality. We did so in a well-defi ned cohort of maintenance HD patients.
Methods and patients
The Medical Ethics Committee at Karolinska University Hospital and Uppsala University approved the study protocol, and all patients consented to participate. This is a post-hoc analysis from the observational Mapping of Infl ammatory Markers in Chronic Kidney Disease (MIMICK) cohort, consisting of prevalent HD patients in the Stockholm region. The protocol has been described elsewhere in more detail. 20, 21 The inclusion period ranged from October 2003 till September 2004.
Laboratory measurements and patient characteristics were gathered at baseline and after 3 months.
From inclusion onward, patients were followed for the occurrence of fatal events. Out of 224 patients originally included in this cohort, TSH, T3 and T4 were not measured in 6 individuals due to limited plasma volume. The patients were on angiotensin-converting enzyme inhibitors and⁄or angiotensin II receptor antagonists (n=72), betablockers (n=109), calcium-channel blockers (n=57), diuretics (n=104), statins (n=72), antiplatelet drugs (n=65), erythropoesis-stimulating agents (n=211), and iron substitution (n=144). Prescribed medication possibly infl uencing thyroid hormone levels was extracted from medical records: 16 patients were receiving levothyroxine and one of these 16 patients additionally used amiodarone. No patients were receiving lithium medication or propranolol. Comorbidity was classifi ed according to Davies et al. 22 , on a seven point scale which was simplifi ed into a three risk category scale (low, medium and high comorbidity risk).
Nutritional status was evaluated by means of the subjective global assessment (SGA).
Causes of death were retrieved from death certifi cates and classifi ed as cardiovascular (CV) or non-CV. CV mortality was defi ned as death due to myocardial ischemia or infarction, cardiac arrest or unknown sudden death, acute as well as chronic heart failure, cerebrovascular accidents, cerebral hemorrhage, and ruptured aortic aneurysm. Non-CV death was defi ned as that not attributable to a cardiovascular origin. Individuals with unknown causes of death (n=13) were grouped within the non-CV group.
Biochemical Methods
Venous blood samples were drawn with the patient in a supine position and stored at -70 °C if not analyzed immediately. Concentrations of high-sensitivity C-reactive protein (CRP) and serum albumin (bromcresol purple) were determined using routine methods at the Department of Laboratory Medicine, Karolinska University Hospital, Huddinge, Sweden. Serum IL-6 concentrations were quantifi ed in an automated immulite analyzer (Siemens Healthcare Diagnostics, Los Angeles, CA, USA). Thyroid hormones levels were also assessed on an Immulite system, using commercially available immunometric assays for T3 [analytical sensitivity (AS), 0.54 nmol/L; total coeffi cient of variation (CVs), 13.2% and 5.4% at the levels of 0.95 and 6.02 nmol/L)], T4 [AS, 5 nmol/L; total CVs, 8.4% and 6.3% at the levels of 49 and 167 nmol/L], and TSH [AS, 0.004 mIU/L; total CVs, 12.5%, and 4.6% at the levels of 0.016 and 1.3 mIU L]. Results are expressed as the average of two measurements.
Statistical Methods
Because existing evidence suggests that up to 70% of ESRD and dialysis patients present with low T3 levels, 3, 5 in our study, we chose to defi ne low T3 or T4 categories as those below the 66th percentile of distribution (higher tertile as the reference group). For the analysis of trimestral thyroid hormone variation (two time points: at study inclusion and after 3 months), we classifi ed patients 6 according to their shift along tertile distribution at each time point, a strategy described in more detail elsewhere 23 and illustrated in Figure 1 . From the nine possible combinations, four groups were created by clustering patients with changes in the same direction: (i) individuals who showed a change to lower tertiles were classifi ed as the 'decrease' group, (ii) individuals showing an increase to upper tertiles were assigned to the 'increase' group, (iii) individuals with both values within the highest tertile of distribution were labeled as a 'persistently high' group and (iv) individuals with both values within the lower or the middle tertile were labelled as a 'persistently low' group.
Differences between groups were tested by means of parametric (independent sample t-test, oneway ANOVA), non-parametric (Mann-Whitney U and Kruskal-Wallis test), and Chi-square tests as appropriate. Correlation was assessed by means of Pearson or Spearman correlation coeffi cients, as appropriate. Intra-patient variability of two measurements is depicted as a coeffi cient of intrapatient variation for each thyroid hormone. Survival during follow-up was analyzed by the Kaplan Meier method and hazard ratios (HR) were calculated with Cox-proportional hazard models with different degrees of adjustment for potential confounders. Age, sex, comorbidity, protein-energy wasting (PEW), serum albumin levels, smoking history, levothyroxine prescription, dialysis vintage, and IL-6 were considered as possible confounders in the associations. In these models, T3, IL-6, and vintage on dialysis were logarithmically transformed because of a non-normal distribution. In order to test whether the effect of T4 levels at baseline and variation groupings on mortality was due to the effect of T3 (in the causal pathway), we performed an additional adjustment for Log T3 or delta T3, respectively. observed for CV mortality. Neither low T3, nor low T4 levels were signifi cantly associated with non-CV mortality. TSH levels did not associate with any outcome measure (data not shown). 
Trimestral thyroid hormone variation and its association with mortality
Thyroid hormones were assessed again after three months in 210 patients. Median (IQR) coeffi cients of intra-patient variation were for T3: 7. Table 3 , general and thyroid specifi c characteristics are depicted across four different T3 variation groups (see Methods), not observing major differences among these groups. The same was true for T4 variation groups (data not shown). In univariate correlation analyses, delta TSH associated with delta IL-6 (rho= 0.17, P=0.01), while delta T3 associated with delta serum albumin (rho=0.22, P=0.01). Figure 2 shows the Kaplan Meier curves for T3 and T4 trimestral variation, both being clearly associated with patient outcome. Patients with persistently low T4 levels showed elevated hazards for all-cause mortality as compared with patients having persistently high T4 levels, an association that reached statistical signifi cance after adjustment for confounders. Higher hazards were observed for prediction of CV-mortality (crude HR 2.6 [1.0 -7.0]). In both cases, further adjustment for trimestral T3 variation (as a continuous variable) did not signifi cantly affect the results. Of note, a decrease in T4 was also associated with elevated hazards for CV-mortality. No association was observed between T4 variation patterns and non-CV mortality. Trimestral TSH variation patterns were not associated with outcome. In a sensitivity analysis, all baseline and longitudinal Cox analyses were repeated in biochemically euthyroid patients only (n=210 at baseline, n=202 with available data at both time points). Additionally, Cox adjustment was done with CRP instead of IL-6. In both cases, results were not different (data not shown).
Discussion
In this study, we show that both basal levels and trimestral variation of T3 and T4 are associated with increased mortality, particularly due to cardiovascular causes. Adjusting in the causal pathway suggests that the mechanisms associating low T4 levels with an elevated mortality rate may be, at least in part, independent of T3 levels.
Our observation linking low basal
T3 levels with increased all-cause mortality is in agreement with some, 5;14;16;17 but not all preceding literature. 15 While earlier studies 5;14;17 only studied the association between T3 and fT3 and all-cause mortality, our study also shows that mortality prediction is mainly attributable to CV causes of death. The lack of mortality prediction observed by Fernandez-Reyes et al. 15 and its strong associations with the infl ammatory status however, make these results diffi cult to contextualize. 24;25 In our own patient population, adjustment for infl ammation (IL-6) and malnutrition (SGA) did not affect this association. Furthermore, Zoccali et al. 14 reported in their study that, since adjustment for fT3 abrogated the association between infl ammation and patient outcome, fT3 may be an intermediate pathological of systemic infl ammation. In our data, as well as in the study conducted by Ozen et al. 5 , adjustment for infl ammation did not affect the link between T3 and mortality. Also, associations between trimestral thyroid hormone changes and variation of infl ammatory markers were somewhat weak and inconsistent in our study. One limitation that makes our studies not fully comparable is, that while Zoccali et al. 14 [26] [27] [28] In support of the association between T3 and the prediction of cardiovascular death in our study, a previous report 11 in patients with moderate to severe kidney disease reported that T3 levels inversely associated with fl ow mediated vasodilatation, and that this observation was dependent on multivariate adjustment for asymmetric dimethylarginine levels. At a cardiac level, low T3 levels in CKD patients are associated with reduced left ventricular function, increased left ventricular mass 13 and elevated intima-media thickness 12 . Our study also adds novel evidence on the suggested impact of trimestral T3 variation on all-cause and CV mortality in ESRD. Patients with persistently low T3 levels exhibited the highest hazards of dying irrespective of other concomitant risk factors. Interestingly, also an increased variation in T3 during the observation period (e.g. both increases and decreases in concentration) resulted in elevated hazards albeit statistically not signifi cant, leading us to hypothesize that also an increased T3 fl uctuation may link to an adverse outcome.
This fi nding accords with a previous study in critically ill patients, 29 in which a fast decline in T3 and T4 (without a concomitant rise in TSH levels) was observed prior to death. Our longitudinal analysis, by including two observations 3 months apart in the same individual, represents a step forward from previous evidence by virtue of observing the subject specifi c temporal order of events. Therefore, it is interesting to pinpoint that fl uctuation of thyroid hormones over time exists in ESRD patients, and that this fl uctuation links to a worse outcome. What factors drive this, and whether uremic thyroid fl uctuation is higher than in other diseases remains, for now, unknown.
Another novelty in our analysis is the association between baseline and trimestral variation of T4 levels and (cardiovascular) mortality. Although this is the fi rst study to report so in a dialysis population, fi ndings are in line with previous evidence in non-renal patients with non-thyroidal illness. 29;30 An interesting aspect in our analysis is that the strength of the association between low T4 levels and mortality was not fully affected by further adjustment for T3 levels. This may suggest that the effect of T4 on outcome is, at least in part, not dependent on its metabolite and that both may participate in the increased CV risk. According to recent literature however, adjusting in the causal pathway may not be so straightforward as initially thought of, 31 and caution is needed in the interpretation of this fi nding which warrants confi rmation in further studies. Nevertheless, our previous report in incident dialysis patients also observed, by means of receiving operator characteristics (ROC) analysis a signifi cant, albeit weak association between T4 levels and all-cause mortality. 16 The recent study by Takamura et al. 32 in euthyroid patients demonstrated that carotid intima-media thickness was inversely and independently associated with T4 and fT4, suggesting an increased cardiovascular risk in subjects with low T4 even within the normal reference range.
Differential effects of T4 and T3 on immune cells have also been reported: T4 stimulated while T3 inhibited peripheral lymphocyte proliferation. 33 In the interpretation of our results, some additional limitations must be addressed: Causes of death were extracted by death records and not confi rmed by autopsies, which could result in some degree of misclassifi cation. As unknown causes of death were denoted as non-CV, this could translate, in any case, into an underestimation of the observed effect towards the null hypothesis, and the true hazards may possibly be bigger. The inclusion of prevalent dialysis patients may infer into a survival bias, although preceding literature contemplates also prevalent patients in their designs.
Finally, ours is an observational study and confounding by unmeasured factors cannot be ruled out.
To conclude, patients with reduced T3 and/or T4 levels bear an increased mortality risk, especially due to cardiovascular causes. This was true when considering both baseline measurements and trimestral variation patterns. Our longitudinal design adds important observational evidence -although non-decisive-that the link may underlie a causal effect.
